Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederroche.com
Investor Update
Get the latest updates from Investor Update directly as they happen.
Follow now 319 followers
Latest posts
Last updated 4 days ago
Reminder: Invitation to Roche’s 3rd Quarter Sales 2024 Presentation
4 days ago
Roche will publish its Sales for the 3rd Quarter of 2024 prior...
Majority of children with spinal muscular atrophy (SMA) treated with Roche’s Evrysdi are able to sit, stand and walk independently, two-year data demonstrate
6 days ago
Positive data confirm Evrysdi efficacy and safety in children first treated pre-symptomatically...
Roche submits science-based targets for net zero by 2045
9 days ago
Basel, 11 October 2024 - Roche announced today its submission of greenhouse...
FDA approves Roche’s Itovebi, a targeted treatment for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation
9 days ago
Approval is based on Phase III INAVO120 results, showing the Itovebi™ (inavolisib)-based...
Invitation: Roche’s Virtual Neurology Investor Event
12 days ago
We are pleased to invite investors and analysts to participate in our...
Positive phase III results for Roche’s Gazyva/Gazyvaro show superiority to standard therapy alone in people with lupus nephritis
24 days ago
Positive phase III results for Roche’s Gazyva/Gazyvaro show superiority to standard therapy...
Roche launches the first test to use its breakthrough TAGS technology for high throughput, simultaneous detection of 12 respiratory viruses
26 days ago
New TAGS (Temperature-Activated Generation of Signal) technology enables up to 15 targets...
Invitation to Roche’s 3rd Quarter Sales 2024 Presentation
27 days ago
Roche will publish its Sales for the 3rd Quarter of 2024 prior...
Reminder: Invitation to Roche’s Pharma Day 2024
about 1 month ago
The Roche Investor Relations team would like to invite you to the...
Positive phase III results show Xofluza significantly reduces the transmission of influenza viruses
about 1 month ago
Data from the CENTERSTONE study shows single-dose Xofluza reduces transmission of influenza...
FDA approves OCREVUS ZUNOVO™ as the first and only twice-a-year 10-minute subcutaneous injection for people with relapsing and progressive multiple sclerosis
about 1 month ago
OCREVUS ZUNOVO™ has the potential to expand treatment options to centres without...
FDA approves Roche’s Tecentriq Hybreza, the first and only subcutaneous anti-PD-(L)1 cancer immunotherapy
about 1 month ago
Tecentriq Hybreza provides patients and physicians with greater flexibility of treatment options...